Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Echo IQ Limited (ASX:EIQ): Cardiac AI Assessments and EchoSolv Regulation

Echo IQ Limited (ASX:EIQ) EchoSolv AS supports assessment of aortic stenosis using cardiac ultrasound data and is intended to assist rather than replace clinical judgement. ThisBusinessmodel is exposed to customer adoption, implementation schedules and theEconomicsof delivering its products or services. Those considerations are distinct …

Aditi Sarkar | 03 November 2026

What Could Actuate Therapeutics' New Oral Tablet Patent Mean for Cancer Drug Elraglusib(NASDAQ:ACTU)

Elraglusib works by inhibiting GSK-3β, an enzyme involved in tumor growth, resistance to chemotherapy, and regulation of immune checkpoints. Until now, the drug has been administered intravenously on weekly or twice-weekly schedules across several studies in patients with refractory and resistant cancers in both …

Sonal Goyal | 03 November 2026

How Alamar Biosciences(NASDAQ:ALMR) Could Unlock Alzheimer's and Parkinson's Early Detection With an 80,000-Sample Study

The formal name of the study is the UK Biobank Proteomics for Risk Identification and Signatures of Brain Health in Midlife — abbreviated as UKB-PRISM. It will be conducted in Nightingale Health's laboratories in Finland, with Alamar's NULISA platform providing the measurement technology. The …

Sonal Goyal | 03 November 2026

Could AN2 Therapeutics' Epetraborole Become a New Treatment Option for Polycythemia Vera(NASDAQ:ANTX)

Polycythemia vera is a blood cancer in which the bone marrow produces excessive red blood cells. The overproduction elevates blood viscosity, increasing the risk of clotting events including stroke and deep vein thrombosis. The primary treatment used today is phlebotomy — the periodic removal …

Sonal Goyal | 03 November 2026

How Axsome Therapeutics Crossed a Billion-Dollar Revenue Run Rate in Q3 2026(NASDAQ:AXSM)

AUVELITY, Axsome's oral NMDA receptor antagonist and sigma-1 receptor agonist, is approved in the US for major depressive disorder in adults and for agitation associated with dementia caused by Alzheimer's disease. Net product sales of $207.6 million in Q3 2026 represented a 53% year-over-year …

Sonal Goyal | 03 November 2026

How Baird Medical's New China Distribution Deal Could Accelerate Microwave Ablation Adoption(NASDAQ:BDMD)

ThePartnershipexpands Baird Medical's coverage in a home market where it has built an establishedLeadershipposition but has historically relied on direct sales infrastructure. The 19 markets included in the agreement represent regions where Baird's direct commercial presence has been limited, suggesting the intent is geographic …

Sonal Goyal | 03 November 2026

What HeartBeam's ALIGN-ACS Pilot Study Results Could Mean for At-Home Heart Attack Detection (NASDAQ:BEAT)

The ALIGN-ACS pilot study enrolled 132 adults at emergency departments of two major cardiology centers in Belgrade, Serbia. Participants were evaluated for acute coronary syndrome, the umbrella term covering heart attacks including myocardial infarction and ST-elevation myocardial infarction. Eight cardiologists independently reviewed both HeartBeam …

Sonal Goyal | 03 November 2026

How BrainsWay Is Scaling Its Noninvasive Mental Health Treatments Through New Clinical Partnerships (NASDAQ:BWAY)

Mindful Health Solutions, now operating under the Radial banner following an August acquisition, manages 27 brain medicine clinic locations spread across California, Missouri, New York, South Carolina, Tennessee, Texas, and Washington. The collaboration with BrainsWay is intended to extend patient access to two key …

Sonal Goyal | 03 November 2026

What Ceribell's Commercial Launch of Delirium Monitoring Could Mean for ICU Brain Care (NASDAQ:CBLL)

Delirium is a neurological condition defined by sudden changes in attention and awareness, and it is far more prevalent in hospital settings than many outside critical care medicine appreciate. Roughly 30% of all ICU patients experience it, and among patients requiring mechanical ventilation, that …

Sonal Goyal | 03 November 2026

What the SEC Registration Effectiveness Means for the Chemomab and Scipher Medicine Merger (NASDAQ:CMMB)

The effectiveness of the S-4 registration statement is a procedural but essential milestone in any transaction structured as a merger requiring shareholder approval. It means the SEC has reviewed the disclosed materials—including the terms of the deal, the financial histories of both companies, and …

Sonal Goyal | 03 November 2026
Support

Hi! How can we help you today?

Loading…